Late Effects research

The Late Effects Clinic is involved in a broad range of research activities with a range of collaborators including prevalence of late effects after stem cell transplantation with an emphasis on cardiovascular risk factors and metabolic health. Psychosocial needs of long-term cancer survivors and quality of life measurements are also a focus of ongoing research and data collection. 

Achievements

​2010: Victorian Public Healthcare Awards, Premier's Excellence Award Improving Cancer Care in Victoria category-Highly Commended. “Improving Quality of Life for Long Term cancer Survivors through support services”

2013: Monash Alfred Psychiatry Research Centre Prize. Impact of pre-transplant psychological distress and coping style on self-reported QoL in long-term survivors of allogeneic SCT

2014: Tour de Cure–Tour recipient, Late Effects Clinic

2014: Henrietta Law Memorial Prize for Allied Health Research. Positive Change for Life. Preliminary results of a 12-month lifestyle intervention program on metabolic syndrome risk factors in haemopoietic SCT survivors

2015: Victorian Public Healthcare Awards: Key Directions in Healthcare Awards–Minister of Health’s Award for excellence in cancer care - "Positive Change for Life"

Our partners

Publications

Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma

Nair AP, Walker P, Kalff A, Bergin K, Hocking J, Avery S, Curtis DJ, Patil S, Das T, Klarica D, Morgan S, Muirhead J, Gorniak M, Reynolds J, Spencer A

(2017), Bone Marrow Transplant,

Impact of allogeneic hematopoietic stem cell transplantation on the HIV reservoir and immune response in three HIV infected individuals

Koelsch KK, Rasmussen TA, Hey-Nguyen WJ, Pearson C, Xu Y, Bailey M, Marks KH, Sasson SC, Taylor MS, Tantau R, Obeid S, Milner B, Morrissey CO, Pinto AN, Suzuki K, Busch MP, Keating SM, Kaiser P, Yukl S, Wong JK, Hiener BM, Palmer S, Zaunders J, Post JJ, Chan DJ, Avery S, Milliken ST, Kelleher AD, Lewin SR, Cooper DA

(2017), J Acquir Immune Defic Syndr,

The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study

Tan P, Soo Tiong I, Fleming S, Pomilio G, Cummings N, Droogleever M, McManus J, Schwarer A, Catalano J, Patil S, Avery S, Spencer A, Wei A

(2017), Oncotarget,

View all publications for Late Effects research